CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

About this update from Cvrx, Inc.

[{"type":"image","alt":"CVRx, Inc.","displaySize":"","headline":null,"caption":"CVRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FkSLvnspvArMoZO8.ZuCnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025.","length":369,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarter","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarter","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue for 2025 was $56.7 million, an increase of 10% over the prior year","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Active implanting centers in the U.S. grew to 252 in 2025, as compared to 223 in the prior year","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated the BENEFIT-HF trial with first enrollments expected in the second quarter of 2026","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":584,"olType":false},{"type":"text","content":""We achieved key foundational goals in 2025, and we're heading into 2026 with increasing momentum. Our sales team is building experience and becoming more effective, and we're seeing strong support at high-potential centers. Additionally, the new Category I CPT codes, effective Jan...

More updates from Cvrx, Inc.